

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61F 13/00		A1	(11) International Publication Number: WO 95/00088 (43) International Publication Date: 5 January 1995 (05.01.95)
(21) International Application Number: PCT/US94/06607 (22) International Filing Date: 22 June 1994 (22.06.94)		(81) Designated States: AU, BB, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LK, LV, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/081,567 23 June 1993 (23.06.93) US 08/227,365 13 April 1994 (13.04.94) US		Published <i>With international search report.</i>	
(71)(72) Applicant and Inventor: MASIZ, John, J. [US/US]; 26 High Street, Topsfield, MA 01983 (US).			
(74) Agents: LEMACK, Kevin, S. et al.; Nields & Lemack, Suite 8, 176 E. Main Street, Westboro, MA 01581 (US).			

(54) Title: **MOLECULAR TRANSDERMAL TRANSPORT SYSTEM**

(57) Abstract

An efficient transdermal delivery system for delivering an active ingredient to the blood supply of a living body, comprising a vasodilator and/or topical counter irritant, an active ingredient, a permeation enhancer for the active ingredient, and a water soluble gum for binding the foregoing. A non-breathable layer also can be used for controlling the microenvironment at the transport site. Compression can be used to further enhance the blood supply at the transport site.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

MOLECULAR TRANSDERMAL TRANSPORT SYSTEMBACKGROUND OF THE INVENTION

Transdermal drug delivery offers many advantages over other types of drug delivery. With transdermal delivery, a localized delivery of drug molecules can be achieved, which makes transdermal drug delivery target specific. Further, transdermal drug delivery avoids the gastro intestinal complications caused by oral delivery. While transdermal drug delivery offers these and other advantages, a system than can quickly and reliably deliver predictable quantities of drug molecules through the skin has heretofore not been developed.

The evolution of transdermal drug delivery has centered around patch technology. Patch technology is based on the ability to hold an active ingredient in constant contact with the epidermis. Over substantial periods of time, drug molecules, held in such a state, will eventually find their way into the bloodstream. Thus, patch technology relies on the ability of the human body to pick up drug molecules through the skin. Transdermal drug delivery using patch technology has recently been applied for delivery of nicotine, in an effort to assist smokers in quitting, the delivery of nitroglycerine to angina sufferers, the delivery of replacement hormones in post menopausal women, etc. These conventional drug delivery systems comprise a patch with an active ingredient such as a drug incorporated therein, the patch also including an adhesive for attachment to the skin so as to place the active ingredient in

close proximity to the skin.

Problems with patch technology abound. First, active drug molecules have a difficult time passing through the skin, as the skin poses a significant barrier. In fact, in order for a drug 5 molecule to reach the bloodstream, it must pass through the epidermis, stratum corneum (an especially dense layer of cells), dermis and capillary cell structure. Second, real world conditions such as the patient's obesity, metabolism and circulatory efficiency can effectively prevent transdermal drug 10 delivery from occurring. Third, patch technology can be used only for treatments involving extensively long treatment periods, since the flow rate of drug molecules is so small. Finally, patch adhesion to the skin causes extensive skin trauma as well 15 as cosmetic problems. Specifically, most adhesives currently used tend to aggressively adhere to the skin so that their removal may cause irritation and trauma. Indeed, subsequent patches used by a given individual are often applied to a different area of the skin in order to minimize such irritation and trauma.

20 In an effort to enhance the efficiency of transdermal drug delivery, the prior art teaches that by mixing certain individual ingredients (penetration enhancers) with a drug molecule, the ability of the drug molecule to pass through the skin is increased somewhat. For example, U.S. Patent No. 4,933,184 25 discloses the use of menthol as a penetration enhancer; U.S. Patent No. 5,229,130 discloses the use of vegetable oil (soybean and/or coconut oil) as a penetration enhancer; and U.S. Patent No. 4,440,777 discloses the use of eucalyptol as a penetration

enhancer.

Although mixing a penetration enhancer with a drug molecule helped to somewhat increase the speed of drug delivery, problems were still present. First, the aforementioned penetration enhancers constitute a passive, not an active, system. Thus, since they were not linked to the drug molecule, the penetration of the enhancer does not necessarily mean that the drug molecule has penetrated. In fact, the prior art drug molecule penetration is only a by-product of the enhancer penetration. Second, even when drug molecule penetration has occurred, the prior art does not establish a condition whereby the blood supply to the transport area is enhanced so as to maximize absorption speed. Third, prior art does not create a molecular structure that releases the drug molecule readily within the acidic medium that constitutes blood, so as to maximize bioavailability of the drug. Finally, although the prior art has increased the speed of transport of the drug molecule transdermally, it is still not sufficiently fast so as to eliminate (if desired) the need for a patch.

It is therefore an object of the present invention to provide a transdermal transport system that efficiently and easily allows for effective delivery of an active ingredient through the skin and into the blood supply of an animal or human.

25

SUMMARY OF THE INVENTION

The problems of the prior art have been overcome by the present invention, which provides an efficient, predictable and reliable active ingredient transdermal delivery system that is

sufficiently fast so as to eliminate (if desired) the need for a patch. More specifically, the present invention creates a molecular transdermal delivery vehicle that contains, as an integral part of the transdermal delivery molecule, the active drug molecule. This molecularly uninhibited lacteal ensemble (or "MULE") is constructed of four elements, namely, a vasodilator, a penetration enhancer, the active ingredient, and a water soluble gum for linking the vasodilator, penetration enhancer and active ingredient.

10 The advantages of the present invention over the prior art are many. First, the creation of a singular molecular unit that contains the drug molecule and transdermally transports it constitutes the first active system. Unlike the prior art, any degree of molecular penetration directly correlates to drug
15 molecule penetration, hence it is also predictable. Second, the MULE enhances blood flow to the transport/application site. Regardless of metabolism, obesity or circulatory efficiency, the vasodilatory aspect of the MULE maximizes blood flow to the transport site so as to reliably maximize absorption of the drug
20 molecule. Third, the MULE is constructed in a manner that when exposed to an acidic medium such as blood, it breaks apart, thereby releasing the drug molecule. This event insures bioavailability so that drug molecules are exposed to the blood supply and are capable of being picked up. Finally, the present
25 invention operates on transport speed that eliminates (if desired) the need for a patch.

DETAILED DESCRIPTION OF THE INVENTION

The invention comprises the creation of an molecular transdermal transport vehicle that has at least four components, including the active ingredient.

5 The first element of the MULE is one that enhances blood flow, through vasodilatory action, and/or through counter irritational action at the transport site. For example, topical counter irritants can be used, which are substances that provide a mild dermal irritation, generally creating a hot or cold 10 sensation in the area of application. This sensation results from the fact that the mild skin irritation brings blood closer to the surface of the skin, and can be utilized to enhance blood supply and effective transport of the active ingredient/carrier. Preferably, the nature and concentration of the counter irritant 15 in the MULE are those established by the Food and Drug Administration in the topical analgesic/topical counter irritant monographs for over-the-counter drugs, which monographs are herein incorporated by reference. For example, the counter irritants should be used in an amount effective for causing an 20 irritation, such as about 1% in the case where natural menthol is used as an external analgesic, and about 1-10% where natural menthol is used as a topical counter irritant. Suitable vasodilators or counter irritants include menthol, methyl salicylate, oil of wintergreen, peppermint oil, and capsicum, 25 with menthol being preferred.

The second element of the MULE is an ingredient that functions as a permeation or penetration enhancer. Suitable enhancers include vegetable oil or a vegetable oil/alcohol mix.

Suitable vegetable oils include peanut oil, olive oil, sunflower oil, soybean oil, monoi oil and macadamia oil, with olive oil being preferred. Suitable alcohols for the vegetable oil/alcohol mix include ethyl alcohol, isopropyl alcohol, methanol and witch hazel. Olive oil mixed with isopropyl alcohol is a preferred vegetable oil/alcohol mix. Eucalyptol is a further suitable example of a vegetable oil/alcohol mix. Suitable ratios of vegetable oil:alcohol range from about 5:1 to about 1:10, preferably 1:2. Suitable amounts of vegetable oil or vegetable oil/alcohol mix in the MULE range from about 1% to about 66% by weight, more preferably from about 10% to about 33.3% by weight.

The third element of the MULE is the active ingredient. The term "active ingredient" is used herein to indicate any material or composition desired to be delivered transdermally, especially drugs. Examples of active ingredients that can be used in accordance with the present invention include acebutolol, acetaminophen, acetohydroxamic acid, acetophenazine, acyclovir, adrenocorticoids, allopurinol, alprazolam, aluminum hydroxide, amantadine, ambenonium, amiloride, aminobenzoate potassium, amobarbital, amoxicillin, amphetamine, ampicillin, androgens, anesthetics, anticoagulants, anticonvulsants-dione type, antithyroid medicine, appetite suppressants, aspirin, atenolol, atropine, azatadine, bacampicillin, baclofen, beclomethasone, belladonna, bendroflumethiazide, benzoyl peroxide, benzthiazide, benztropine, betamethasone, bethanechol, biperiden, bisacodyl, bromocriptine, bromodiphenhydramine, brompheniramine, buclizine, bumetanide, busulfan, butabarbital, butaperazine, caffeine, calcium carbonate, captopril, carbamazepine, carbenicillin,

carbidopa & levodopa, carbinoxamine inhibitors, carbonic anhydase, carisoprodol, carphenazine, cascara, cefaclor, cefadroxil, cephalexin, cephadrine, chlophedianol, chloral hydrate, chlorambucil, chloramphenicol, chlordiazepoxide, 5 chloroquine, chlorothiazide, chlorotrianisene, chlorpheniramine, chlorpromazine, chlorpropamide, chlorprothixene, chlorthalidone, chlorzoxazone, cholestyramine, cimetidine, cinoxacin, clemastine, clidinium, clindamycin, clofibrate, clomiphene, clonidine, 10 clorazepate, cloxacillin, colochicine, coloestipol, conjugated estrogen, contraceptives, cortisone, cromolyn, cyclacillin, cyclandelate, cyclizine, cyclobenzaprine, cyclophosphamide, cyclothiazide, cycrimine, cyproheptadine, danazol, danthron, dantrolene, dapsone, dextroamphetamine, dexamethasone, 15 dexchlorpheniramine, dextromethorphan, diazepan, dicloxacillin, dicyclomine, diethylstilbestrol, diflunisal, digitalis, diltiazen, dimenhydrinate, dimethindene, diphenhydramine, diphenidol, diphenoxylate & atropine, diphenylopyraline, dipyradamole, disopyramide, disulfiram, divalporex, docusate calcium, docusate potassium, docusate sodium, doxyloamine, 20 dronabinol ephedrine, epinephrine, ergoloidmesylates, ergonovine, ergotamine, erythromycins, esterified estrogens, estradiol, estrogen, estrone, estropipate, etharynic acid, ethchlorvynol, ethinyl estradiol, ethopropazine, ethosaximide, ethotoxin, fenoprofen, ferrous fumarate, ferrous gluconate, ferrous sulfate, 25 flavoxate, flecainide, fluphenazine, fluprednisolone, flurazepam, folic acid, furosemide, gemfibrozil, glipizide, glyburide, glycopyrrolate, gold compounds, griseofuwin, guaifenesin, guanabenz, guanadrel, guanethidine, halazepam, haloperidol,

hetacillin, hexobarbital, hydralazine, hydrochlorothiazide,
hydrocortisone (cortisol), hydroflunethiazide,
hydroxychloroquine, hydroxyzine, hyoscyamine, ibuprofen,
indapamide, indomethacin, insulin, iofoquinol, iron-
5 polysaccharide, isoetharine, isoniazid, isopropamide
isoproterenol, isotretinoin, isoxsuprine, kaolin & pectin,
ketoconazole, lactulose, levodopa, lincomycin liothyronine,
liotrix, lithium, loperamide, lorazepam, magnesium hydroxide,
10 magnesium sulfate, magnesium trisilicate, maprotiline, meclizine,
meclofenamate, medroxyproyesterone, melenamic acid, melphalan,
mephénytoin, mephobarbital, meprobamate, mercaptopurine,
mesoridazine, metaproterenol, metaxalone, methamphetamine,
methaqualone, metharbital, methenamine, methicillin,
methocarbamol, methotrexate, methsuximide, methyclothinzide,
15 methylcellulos, methyldopa, methylergonovine, methylphenidate,
methylprednisolone, methysergide, metoclopramide, metolazone,
metoprolol, metronidazole, minoxidil, mitotane, monamine oxidase
inhibitors, nadolol, nafcillin, nalidixic acid, naproxen,
narcotic analgesics, neomycin, neostigmine, niacin, nicotine,
20 nifedipine, nitrates, nitrofurantoin, nomifensine, norethindrone,
norethindrone acetate, norgestrel, nylidrin, nystatin,
orphenadrine, oxacillin, oxazepam, oxprenolol, oxymetazoline,
oxyphenbutazone, pancrelipase, pantothenic acid, papaverine,
para-aminosalicylic acid, paramethasone, paregoric, pemoline,
25 penicillamine, penicillin, penicillin-v, pentobarbital,
perphenazine, phenacetin, phenazopyridine, pheniramine,
phenobarbital, phenolphthalein, phenprocoumon, phenoxisimide,
phenylbutazone, phenylephrine, phenylpropanolamine, phenyl

toloxamine, phenytoin, pilocarpine, pindolol, piper acetazine,
piroxicum, poloxamer, polycarbophil calcium, polythiazide,
potassium supplements, pruzepam, prazosin, prednisolone,
prednisone, primidone, probenecid, probucol, procainamide,
5 procarbazine, prochlorperazine, procyclidine, promazine,
promethazine, propantheline, propranolol, pseudoephedrine,
psoralens, psyllium, pyridostigmine, pyrodoxine, pyrilamine,
pyrvinium, quinestrol, quinethazone, quinidine, quinine,
ranitidine, rauwolfia alkaloids, riboflavin, rifampin, ritodrine,
10 salicylates, scopolamine, secobarbital, senna, sannosides a & b,
simethicone, sodium bicarbonate, sodium phosphate, sodium
fluoride, spironolactone, sucrufluate, sulfacytine,
sulfamethoxazole, sulfasalazine, sulfapyrazone, sulfisoxazole,
sulindac, talbutal, tamazepam, terbutaline, terfenadine,
15 terphinhhydrate, teracyclines, thiabendazole, thiamine,
thioridazine, thiothixene, thyroblobulin, thyroid, thyroxine,
ticarcillin, timolol, tocainide, tolazamide, tolbutamide,
tolmetin trozodone, tretinoiin, triamcinolone, trianterene,
triazolam, trichlormethiazide, tricyclic antidepressants,
20 tridhexethyl, trifluoperazine, triflupromazine, trihexyphenidyl,
trimeprazine, trimethobenzamine, trimethoprim, tripclennamine,
triprolididine, valproic acid, verapamil, vitamin A, vitamin B-12,
vitamin C, vitamin D, vitamin E, vitamin K and xanthine.

The final element that is essential to the creation of the
25 MULE is the addition of a water soluble gum. The water soluble
gum binds the first three elements of the MULE together into the
singular transport vehicle. Suitable water-soluble gums include
agar, arabic, carob, CMC, carrageenans, ghatti, guar, karaya,

kadaya, locust bean, tragacanth and xanthan gums. The water soluble gum should be used in an amount ranging from about 1% to about 33.3% by weight, most preferably an amount equal to the amount of active ingredient used.

5 The MULE is created by placing the penetration enhancer, the vasodilatory and/or counter irritant, and the active ingredient in a mixing vessel, and agitating the combination over a sufficient period to achieve a uniform mix. The water soluble gum is then slowly added while continuing the agitation. After
10 completion of the gum addition, agitation continues until mix uniformity is achieved. Other inactive ingredients may be added if desired.

15 Although the MULE transports drug molecules so efficiently that the need for a patch is obviated, a patch can still be used where desired. Pre-packaged patches, pre-impregnated with the MULE can make presorbed doses controllable. However, if a patch is used in conjunction with the MULE of the present invention, preferably the patch is a non-breathable layer on which the active ingredient is placed. Suitable non-breathable layers
20 include sheets of plastic, polyethylene, polyvinyl chloride, wax paper, foil, latex, etc., and combinations thereof. Those skilled in the art will recognize that any non-breathable substance (defined as a substance that does not allow the exchange of gases through its membrane) that is not deleterious to the particular active ingredient being used and that does not cause any irritation upon contact with skin can be used.
25

 The non-breathable layer functions to create and control a suitable microenvironment at the transport site. Too cold an

environment can result in little blood supply to the dermal barrier; pores and other natural openings in the dermal barrier constrict, thereby preventing efficient transport. Too hot an environment can enhance secretion and perspiration and vapor flow through the dermal barrier, creating negative transport activity. 5 Too dry an environment can cause an element or elements of the MULE to evaporate quickly, losing its ability to transport. The enhanced evaporation also creates negative transport pressure. Too humid an environment can cause dilution of the active 10 ingredient, diminishing the capacity of the active ingredient and also creating negative transport activity.

The non-breathable layer captures the body temperature and humidity, thereby maintaining temperature at the most efficient for transport, the pore size at or close to a maximum, and normal 15 blood flow to the site. In addition, since body vapor is captured, a proper moisture level is maintained. Preferably the temperature and humidity at the transport site is about 85-100°F and 50-99%, respectively. The non-breathable layer also creates a positive osmotic pressure back through the dermal layer, acting 20 in a manner analogous to the so-called "greenhouse effect". Vapor admitted through the skin passes through the MULE, collects along the non-breathable barrier and then passes back through the MULE and through the skin. Since the temperature is at about the body temperature, the pore size is maximized and blood flow is 25 sufficient so that the active ingredient can be easily picked up by the blood through the dermal layer. If desired, the non-breathable layer can be secured to the skin by any suitable means, such as with a bandage having adhesive or fasteners. In

the preferred embodiment, no adhesive is used, instead compression is used as discussed in detail below.

In order to further enhance blood supply to the transport site, compression can be utilized. Specifically, the non-breathable layer can be applied to the skin tightly, such as with a tightly wrapped bandage. Preferably the compression at the transport site is greater than zero pounds per square inch but less than about 10 pounds per square inch. Too much compression can result in restricted blood supply. The positive pressure applied also aids in forcing the MULE through the dermal layer and into contact with the blood supply.

The non-breathable layer and wrapping material can be conveniently designed to accommodate specific transport sites. For example, the non-breathable layer and wrap can be shaped in the form of a glove to be worn on one hand of the individual, or can be shaped in the form of a band to be worn on the arm or leg of the individual.

EXAMPLE 1

Vegetable oil, natural menthol and the active ingredient are placed in a mixing vessel. The contents are then agitated therein to achieve a uniform blend. Xanthan gum is then added slowly with the mixing vessel contents being continually agitated. The agitation continues until a uniform blend is achieved. Other inactive ingredients may be added, and again the contents mixed until uniformity is achieved.

The contents are removed from the mixing vessel and are applied directly to the skin at the desired transport site by

gentle massaging for approximately 60 seconds or until the mixture disappears.

What is claimed is:

1. A transdermal delivery system for delivering an active ingredient through the skin of a living body, comprising:

- a. an active ingredient;
- 5 b. first means for enhancing the blood supply to the site of transport of said active ingredient through said skin;
- c. second means for enhancing the permeation of said active ingredient through said skin; and
- 10 d. third means for binding said active ingredient and said first and second means into a singular transport vehicle.

2. The transdermal delivery system of claim 1, wherein said first means for enhancing the blood supply comprises a topical counter irritant.

15 3. The transdermal delivery system of claim 2, wherein said topical counter irritant is selected from the group consisting of menthol, methyl salicylate, oil of wintergreen, peppermint oil and capsicum.

20 4. The transdermal delivery system of claim 1, wherein said second means for enhancing the permeation comprises a vegetable oil.

25 5. The transdermal delivery system of claim 2, wherein said second means for enhancing the permeation comprises a vegetable oil.

6. The transdermal delivery system of claim 4, wherein said second means is selected from the group consisting of peanut oil, olive oil, sunflower oil, soybean oil, monoi oil, macadamia oil

and a vegetable oil/alcohol mix.

7. The transdermal delivery system of claim 5, wherein said second means is selected from the group consisting of peanut oil, olive oil, sunflower oil, soybean oil, monoi oil, macadamia oil and a vegetable oil/alcohol mix.

8. The transdermal delivery system of claim 1, wherein said third means comprises a water-soluble gum.

9. The transdermal delivery system of claim 2, wherein said third means comprises a water-soluble gum.

10 10. The transdermal delivery system of claim 5, wherein said third means comprises a water-soluble gum.

11. The transdermal delivery system of claim 8, wherein said water-soluble gum is selected from the group consisting of agar, arabic, carob, CMC, carrageenans, ghatti, guar, karaya, 15 kadaya, locust bean, tragacanth and xanthan gum.

12. The transdermal delivery system of claim 9, wherein said water-soluble gum is selected from the group consisting of agar, arabic, carob, CMC, carrageenans, ghatti, guar, karaya, kadaya, locust bean, tragacanth and xanthan gum.

20 13. The transdermal delivery system of claim 10, wherein said water-soluble gum is selected from the group consisting of agar, arabic, carob, CMC, carrageenans, ghatti, guar, karaya, kadaya, locust bean, tragacanth and xanthan gum.

14. The transdermal delivery system of claim 1, further 25 comprising means for controlling the temperature and humidity at the site of transport of said active ingredient through said skin.

15. The transdermal delivery system of claim 14, wherein

said means for controlling the temperature and humidity comprises a non-breathable layer.

16. A method of delivering an active ingredient through the skin of a living body, comprising:

- 5 a. placing the active ingredient on the skin at a transport site;
- b. enhancing the blood supply to the site of transport of said active ingredient through said skin by causing a skin irritation at said site; and
- 10 c. enhancing the permeation of said active ingredient through said skin by binding said active ingredient to a carrier with a water-soluble gum.

17. The method of claim 16, further comprising controlling the temperature and humidity at said transport site.

15 18. The method of claim 17, wherein said temperature and humidity are controlled by covering said transport site with a non-breathable material.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US94/06607

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : A61F 13/00

US CL : 424/449

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/449, 447, 448

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS menthol, methylsalicylate, transdermal, agar, carrageenan, tragacanth, xanthan

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 4,933,184 (TSUK) 12 June 1990, see column 2, lines 35-44 and column 5, lines 35-45.	1-3
--		-----
Y		4-18
Y,P	US, A, 5,229,130 (SHARMA ET AL) 20 July 1993, see column 2, lines 31-36; column 3, lines 1-8; column 6, lines 33-55.	1-7,14,15, 17,18
Y	THE MERCK INDEX: (WINDHOLZ), 1983, 10TH edition; "AN ENCYCLOPEDIA OF CHEMICALS, DRUGS, AND BIOLOGICALS", see pages 260, 660 and 1444.	1,8-13,16
A	US, A, 4,910,020 (SAMOUR) 20 March 1990, see entire document.	14,15,17, 18
A	US, A, 4,788,061 (SHORE) 29 November 1988, see entire document.	14,15,17, 18

 Further documents are listed in the continuation of Box C. See patent family annex.

•	Special categories of cited documents:		
•A*	document defining the general state of the art which is not considered to be part of particular relevance	•T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
•E*	earlier document published on or after the international filing date	•X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
•L*	document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	•Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
•O*	document referring to an oral disclosure, use, exhibition or other means	•Z*	document member of the same patent family
•P*	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

17 AUGUST 1994

Date of mailing of the international search report

26 SEP 1994

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
D. GABRIELLE PHELAN

Telephone No. (703) 308-2351

Form PCT/ISA/210 (second sheet)(July 1992)*

THIS PAGE BLANK (USPTO)